EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Multiple or Single Endocrine Abnormalities Associated With Immune Checkpoint Inhibitors

Fumika Kamitani iD, Yuichi Nishioka iD, Hiroki Nakajima iD, Yukako Kurematsu, Sadanori Okada iD, Tomoya Myojin iD, Tatsuya Noda iD, Tomoaki Imamura iD, Yutaka Takahashi iD

The Journal of Clinical Endocrinology & Metabolism · 18.12.2025 · 111 (1) · 54-61

DOI: 10.1210/clinem/dgaf347 ↗

Kurz gefasst

Fachartikel in der Zeitschrift The Journal of Clinical Endocrinology & Metabolism, online erschienen am 12.06.2025. Verfasst von Fumika Kamitani und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Diabetes and Endocrinology, Nara Medical University, Kashihara, Nara 634-8522, Japan. Hauptthemen laut MEDLINE: Immune Checkpoint Inhibitors, Endocrine System Diseases, Neoplasms. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 44 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: JSPS, KAKENHI, Japan Association for Diabetes Education and Care.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Immune checkpoint inhibitors (ICIs) are associated with various endocrine abnormalities. However, their underlying pathophysiology remains unclear. We investigated the effect of multiple endocrine abnormalities on the overall survival (OS) of patients treated with ICIs.

Methods

In total, 12 978 patients who received ICIs between 2014 and 2022 were investigated using the DeSC Japanese administrative claims database. Endocrine abnormalities were defined by each hormone replacement therapy, including levothyroxine, hydrocortisone, and insulin, in which it is difficult to distinguish central or primary hormone defect. Also, only patients with hypothyroidism after thyroiditis were included. Type 1 diabetes was additionally defined by the name of the disease and strict self-injection fees. Regression analyses were performed to identify risk factors for endocrine abnormalities and the effect of endocrine abnormalities on OS, adjusting for confounders including the number and duration of ICI administrations.

Results

Single and multiple endocrine abnormalities were observed in 12.0% and 1.4% of patients, respectively. The most common combination was hypothyroidism and adrenal insufficiency (1.3%). Kaplan–Meier analysis indicated better survival in patients with multiple and single endocrine abnormalities than in those without (P < .01). Multivariable analysis revealed lower mortality in patients with multiple and single endocrine abnormalities [adjusted hazard ratio (aHR) 0.39; 95% confidence interval (CI), 0.28-0.54, P < .01; aHR 0.65; 95% CI, 0.5-80.72, P < .01, respectively) than in those without. Mortality was significantly lower with multiple abnormalities than with single (aHR 0.56; 95% CI, 0.39-0.79, P < .01).

Conclusion

The development of multiple endocrine abnormalities in patients treated with ICIs is associated with improved survival compared with that of patients with a single abnormality.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Immune Checkpoint InhibitorsEndocrine System DiseasesNeoplasmsHumansFemaleMaleAgedMiddle AgedJapanRetrospective StudiesAdultAged, 80 and overSurvival RateRisk FactorsHypothyroidismPrognosisKaplan-Meier EstimateFollow-Up Studies

Stichwörter der Autor:innen

diabeteshypophysitisimmune checkpoint inhibitormultiple endocrine abnormalitiesthyroiditis

Substanzen

Immune Checkpoint Inhibitors

Autor:innen und Institutionen

  • Department of Diabetes and Endocrinology, Nara Medical University, Kashihara, Nara 634-8522, Japan.
  • Department of Public Health, Health Management and Policy, Nara Medical University, Kashihara, Nara 634-8521, Japan.

ORCID-Profile: Fumika Kamitani, Yuichi Nishioka, Hiroki Nakajima, Sadanori Okada, Tomoya Myojin, Tatsuya Noda, Tomoaki Imamura, Yutaka Takahashi

Förderung

  • JSPS
  • KAKENHI
  • Japan Association for Diabetes Education and Care

Zitieren

APA

Kamitani, F., Nishioka, Y., Nakajima, H., Kurematsu, Y., Okada, S., Myojin, T., Noda, T., Imamura, T., & Takahashi, Y. (2025). Multiple or Single Endocrine Abnormalities Associated With Immune Checkpoint Inhibitors. The Journal of Clinical Endocrinology & Metabolism, 111(1), 54-61. https://doi.org/10.1210/clinem/dgaf347

Vancouver

Kamitani F, Nishioka Y, Nakajima H, Kurematsu Y, Okada S, Myojin T, et al. Multiple or Single Endocrine Abnormalities Associated With Immune Checkpoint Inhibitors. The Journal of Clinical Endocrinology & Metabolism. 2025;111(1):54-61. doi:10.1210/clinem/dgaf347

BibTeX
@article{Kamitani2025,
  author = {Kamitani, Fumika and Nishioka, Yuichi and Nakajima, Hiroki and Kurematsu, Yukako and Okada, Sadanori and Myojin, Tomoya and Noda, Tatsuya and Imamura, Tomoaki and Takahashi, Yutaka},
  title = {Multiple or Single Endocrine Abnormalities Associated With Immune Checkpoint Inhibitors},
  journal = {The Journal of Clinical Endocrinology & Metabolism},
  year = {2025},
  volume = {111},
  number = {1},
  pages = {54--61},
  doi = {10.1210/clinem/dgaf347}
}
Kostenlos starten →